Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …

Colistin regained global interest as a consequence of the rising prevalence of multidrug-
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …

The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the
1950s and thus did not undergo contemporary drug development procedures. Their clinical …

Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …

Colistin (Polymyxin E) is one of the few cationic antimicrobial peptides commercialized in
both human and veterinary medicine. For several years now, colistin has been considered …

Rational use of antibiotic is the key approach to improve the antibiotic performance and
tackling of the antimicrobial resistance. The efficacy of antimicrobials are influenced by many …

Colistin is a polymyxin antibiotic that was discovered in the late 1940s for the treatment of
gram‐negative infections. After several years of clinical use, its popularity diminished …

Pharmacokinetic-pharmacodynamic (PKPD) modeling and simulation has evolved as an
important tool for rational drug development and drug use, where developed models …

ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …

Colistin is a complex polypeptide antibiotic composed mainly of colistin A and B. It was
abandoned from clinical use in the 1970s because of significant renal and, to a lesser …